Work

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers

Year: 2023

Type: article

Abstract: This exploratory analysis of a randomized clinical trial evaluates the effect of neprilysin inhibition on Alzheimer disease blood biomarkers in patients with heart disease.

Source: JAMA Neurology

DOI: 10.1001/jamaneurol.2023.4719

Authors: Wagner S. Brum, Kieran F. Docherty, Nicholas J. Ashton, Henrik Zetterberg, Oskar Hansson, John J. V. McMurray, Kaj Blennow

Institutions: Universidade Federal do Rio Grande do Sul, University of Gothenburg, University of Glasgow, King's College London, Stavanger University Hospital, National Institute for Health and Care Research, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, Lund University

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,140

Funders: Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, British Heart Foundation, European Commission, Lunds Universitet, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, National Institute on Aging

Awards: The effects of sacubitril / valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised, double- blinded active-comparator cardiac-MR based trial, G581591135

OpenAlex ID: W4389891613

FWCI: 9.38

Cites: 6

Cited by: 65

Related to: 10